| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |